Altrenogest

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Altrenogest
Accession Number
DB11372
Type
Small Molecule
Groups
Vet approved
Description

Altrenogest, also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals.

Structure
Thumb
Synonyms
  • 17-alpha-Allyl-estratriene-4,9,11,17-beta-ol-3-one
  • Allyl trenbolone
  • Allyltrenbolone
  • Altrenogestum
External IDs
A-35957 / DRC 6246 / R 2267 / RU 2267 / RU-2267
Categories
UNII
2U0X0JA2NB
CAS number
850-52-2
Weight
Average: 310.437
Monoisotopic: 310.193280077
Chemical Formula
C21H26O2
InChI Key
VWAUPFMBXBWEQY-ANULTFPQSA-N
InChI
InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
IUPAC Name
(1R,3aS,3bS,11aS)-1-hydroxy-11a-methyl-1-(prop-2-en-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinAltrenogest may decrease the anticoagulant activities of (R)-warfarin.
(S)-WarfarinAltrenogest may decrease the anticoagulant activities of (S)-Warfarin.
4-hydroxycoumarinAltrenogest may decrease the anticoagulant activities of 4-hydroxycoumarin.
AbciximabAltrenogest may decrease the anticoagulant activities of Abciximab.
AcenocoumarolAltrenogest may decrease the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAltrenogest may decrease the anticoagulant activities of Acetylsalicylic acid.
AlteplaseAltrenogest may decrease the anticoagulant activities of Alteplase.
AmediplaseAltrenogest may decrease the anticoagulant activities of Amediplase.
AnagrelideAltrenogest may decrease the anticoagulant activities of Anagrelide.
AncrodAltrenogest may decrease the anticoagulant activities of Ancrod.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Machnik M, Hegger I, Kietzmann M, Thevis M, Guddat S, Schanzer W: Pharmacokinetics of altrenogest in horses. J Vet Pharmacol Ther. 2007 Feb;30(1):86-90. [PubMed:17217407]
  2. Kornheiser KM: Use of altrenogest in mares. J Am Vet Med Assoc. 1989 May 1;194(9):1150. [PubMed:2722647]
  3. Hodgson D, Howe S, Jeffcott L, Reid S, Mellor D, Higgins A: Effect of prolonged use of altrenogest on behaviour in mares. Vet J. 2005 May;169(3):322-5. [PubMed:15912604]
  4. Webel SK, Squires EL: Control of the oestrous cycle in mares with altrenogest. J Reprod Fertil Suppl. 1982;32:193-8. [PubMed:6962854]
  5. Soede NM, Bouwman EG, Langendijk P, van der Laan I, Kanora A, Kemp B: Follicle development during luteal phase and altrenogest treatment in pigs. Reprod Domest Anim. 2007 Jun;42(3):329-32. [PubMed:17506814]
  6. Sigler DH, Ericson DE, Gibbs PG, Kiracofe GH, Stevenson JS: Reproductive traits, lactation and foal growth in mares fed altrenogest. J Anim Sci. 1989 May;67(5):1154-9. [PubMed:2737975]
  7. Stevenson JS, Davis DL, Pollmann DS: Altrenogest and fat for summer breeding of primiparous sows. J Anim Sci. 1985 Aug;61(2):480-6. [PubMed:4044446]
  8. dos Santos JM, Wentz I, Bortolozzo FP, Barioni W Jr: Early-weaned sows: altrenogest therapy, estrus, ovulation, and reproductive performance. Anim Reprod Sci. 2004 Sep;84(3-4):407-13. [PubMed:15302382]
  9. Davis DL, Stevenson JS, Schmidt WE: Scheduled breeding of gilts after estrous synchronization with altrenogest. J Anim Sci. 1985 Mar;60(3):599-602. [PubMed:3988636]
  10. Rhodes MT, Davis DL, Stevenson JS: Flushing and altrenogest affect litter traits in gilts. J Anim Sci. 1991 Jan;69(1):34-40. [PubMed:2005028]
External Links
KEGG Drug
D02840
ChemSpider
8216634
ChEMBL
CHEMBL1315492
Wikipedia
Altrenogest

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0301 mg/mLALOGPS
logP3.74ALOGPS
logP3.2ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)18.4ChemAxon
pKa (Strongest Basic)-0.18ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity95.46 m3·mol-1ChemAxon
Polarizability36.06 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-oxosteroid / Hydroxysteroid / 17-hydroxysteroid / Oxosteroid / Cyclohexenone / Cyclic alcohol / Tertiary alcohol / Cyclic ketone / Ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:13 / Updated on December 02, 2019 09:01